Theranostic biomarkers and PARP-inhibitors effectiveness in patients with non-BRCA associated homologous recombination deficient tumors : Still looking through a dirty glass window?
Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved..
Breast cancer susceptibility gene 1 (BRCA1) and breast cancer susceptibility gene 2 (BRCA2) deleterious variants were the first and, still today, the main biomarkers of poly(ADP)ribose polymerase (PARP)-inhibitors (PARPis) benefit. The recent, increased, numbers of individuals referred for counseling and multigene panel testing, and the remarkable expansion of approved PARPis, not restricted to BRCA1/BRCA2-Pathogenic Variants (PVs), produced a strong clinical need for non-BRCA biomarkers. Significant limitations of the current testing and assays exist. The different approaches that identify the causes of Homologous Recombination Deficiency (HRD), such as the germline and somatic Homologous Recombination Repair (HRR) gene PVs, the testing showing its consequences, such as the genomic scars, or the novel functional assays such as the RAD51 foci testing, are not interchangeable, and should not be considered as substitutes for each other in clinical practice for guiding use of PARPi in non-BRCA, HRD-associated tumors. Today, the deeper knowledge on the significant relationship among all proteins involved in the HRR, not limited to BRCA, expands the possibility of a successful non-BRCA, HRD-PARPi synthetic lethality and, at the same time, reinforces the need for enhanced definition of HRD biomarkers predicting the magnitude of PARPi benefit.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:121 |
|---|---|
| Enthalten in: |
Cancer treatment reviews - 121(2023) vom: 15. Dez., Seite 102650 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Incorvaia, Lorena [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 27.11.2023 Date Revised 27.11.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ctrv.2023.102650 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36431186X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36431186X | ||
| 003 | DE-627 | ||
| 005 | 20231226095154.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ctrv.2023.102650 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1214.xml |
| 035 | |a (DE-627)NLM36431186X | ||
| 035 | |a (NLM)37939446 | ||
| 035 | |a (PII)S0305-7372(23)00143-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Incorvaia, Lorena |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Theranostic biomarkers and PARP-inhibitors effectiveness in patients with non-BRCA associated homologous recombination deficient tumors |b Still looking through a dirty glass window? |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.11.2023 | ||
| 500 | |a Date Revised 27.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved. | ||
| 520 | |a Breast cancer susceptibility gene 1 (BRCA1) and breast cancer susceptibility gene 2 (BRCA2) deleterious variants were the first and, still today, the main biomarkers of poly(ADP)ribose polymerase (PARP)-inhibitors (PARPis) benefit. The recent, increased, numbers of individuals referred for counseling and multigene panel testing, and the remarkable expansion of approved PARPis, not restricted to BRCA1/BRCA2-Pathogenic Variants (PVs), produced a strong clinical need for non-BRCA biomarkers. Significant limitations of the current testing and assays exist. The different approaches that identify the causes of Homologous Recombination Deficiency (HRD), such as the germline and somatic Homologous Recombination Repair (HRR) gene PVs, the testing showing its consequences, such as the genomic scars, or the novel functional assays such as the RAD51 foci testing, are not interchangeable, and should not be considered as substitutes for each other in clinical practice for guiding use of PARPi in non-BRCA, HRD-associated tumors. Today, the deeper knowledge on the significant relationship among all proteins involved in the HRR, not limited to BRCA, expands the possibility of a successful non-BRCA, HRD-PARPi synthetic lethality and, at the same time, reinforces the need for enhanced definition of HRD biomarkers predicting the magnitude of PARPi benefit | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a BRCA | |
| 650 | 4 | |a Breast cancer | |
| 650 | 4 | |a Homologous recombination deficiency | |
| 650 | 4 | |a Homologous recombination repair | |
| 650 | 4 | |a Ovarian cancer | |
| 650 | 4 | |a PARP-inhibitors | |
| 650 | 7 | |a Poly(ADP-ribose) Polymerase Inhibitors |2 NLM | |
| 650 | 7 | |a BRCA2 Protein |2 NLM | |
| 650 | 7 | |a BRCA1 Protein |2 NLM | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 700 | 1 | |a Perez, Alessandro |e verfasserin |4 aut | |
| 700 | 1 | |a Marchetti, Claudia |e verfasserin |4 aut | |
| 700 | 1 | |a Brando, Chiara |e verfasserin |4 aut | |
| 700 | 1 | |a Gristina, Valerio |e verfasserin |4 aut | |
| 700 | 1 | |a Cancelliere, Daniela |e verfasserin |4 aut | |
| 700 | 1 | |a Pivetti, Alessia |e verfasserin |4 aut | |
| 700 | 1 | |a Contino, Silvia |e verfasserin |4 aut | |
| 700 | 1 | |a Di Giovanni, Emilia |e verfasserin |4 aut | |
| 700 | 1 | |a Barraco, Nadia |e verfasserin |4 aut | |
| 700 | 1 | |a Bono, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Giurintano, Ambra |e verfasserin |4 aut | |
| 700 | 1 | |a Bazan Russo, Tancredi Didier |e verfasserin |4 aut | |
| 700 | 1 | |a Gottardo, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Cutaia, Sofia |e verfasserin |4 aut | |
| 700 | 1 | |a Pedone, Erika |e verfasserin |4 aut | |
| 700 | 1 | |a Peri, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a Corsini, Lidia Rita |e verfasserin |4 aut | |
| 700 | 1 | |a Fanale, Daniele |e verfasserin |4 aut | |
| 700 | 1 | |a Galvano, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Scambia, Giovanni |e verfasserin |4 aut | |
| 700 | 1 | |a Badalamenti, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Russo, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Bazan, Viviana |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer treatment reviews |d 1993 |g 121(2023) vom: 15. Dez., Seite 102650 |w (DE-627)NLM000409189 |x 1532-1967 |7 nnns |
| 773 | 1 | 8 | |g volume:121 |g year:2023 |g day:15 |g month:12 |g pages:102650 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ctrv.2023.102650 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 121 |j 2023 |b 15 |c 12 |h 102650 | ||